Correction: Girard et al. Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis. Cancers 2024, 16, 2492
, , , , Addition of an Author
- Author Contributions: N.G. provided clinical expertise and oversight for the study. M.B., S.G. and G.L.-O. contributed to the writing and to the design and interpretation of the analysis. B.R. performed the data analysis and contributed to the writing, design, and interpretation of the analysis. S.L., L.V. and M.A.C. contextualized the findings and contributed to the design and interpretation of the analysis. M.T., N.V., J.M.L. and J.S. provided clinical insights and contextualized the findings. N.W. and W.W.Y. conducted the systematic literature review. All authors have read and agreed to the published version of the manuscript.
Reference
- Girard, N.; Besada, M.; Rogula, B.; Lucherini, S.; Vo, L.; Chaudhary, M.A.; Goring, S.; Lozano-Ortega, G.; Tran, M.; Varol, N.; et al. Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis. Cancers 2024, 16, 2492. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Girard, N.; Besada, M.; Rogula, B.; Lucherini, S.; Vo, L.; Chaudhary, M.A.; Goring, S.; Lozano-Ortega, G.; Tran, M.; Varol, N.; et al. Correction: Girard et al. Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis. Cancers 2024, 16, 2492. Cancers 2025, 17, 674. https://doi.org/10.3390/cancers17040674
Girard N, Besada M, Rogula B, Lucherini S, Vo L, Chaudhary MA, Goring S, Lozano-Ortega G, Tran M, Varol N, et al. Correction: Girard et al. Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis. Cancers 2024, 16, 2492. Cancers. 2025; 17(4):674. https://doi.org/10.3390/cancers17040674
Chicago/Turabian StyleGirard, Nicolas, Mariam Besada, Basia Rogula, Stefano Lucherini, Lien Vo, Mohammad A. Chaudhary, Sarah Goring, Greta Lozano-Ortega, Mia Tran, Nebibe Varol, and et al. 2025. "Correction: Girard et al. Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis. Cancers 2024, 16, 2492" Cancers 17, no. 4: 674. https://doi.org/10.3390/cancers17040674
APA StyleGirard, N., Besada, M., Rogula, B., Lucherini, S., Vo, L., Chaudhary, M. A., Goring, S., Lozano-Ortega, G., Tran, M., Varol, N., Waser, N., Yu, W. W., Lee, J. M., & Spicer, J. (2025). Correction: Girard et al. Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis. Cancers 2024, 16, 2492. Cancers, 17(4), 674. https://doi.org/10.3390/cancers17040674
